Unlabelled: Cardiovascular risk (CR) is associated with obstructive sleep apnea hypopnea syndrome (OSAHS). This association enhances the risk of major adverse cardiovascular events (MACE); nevertheless, data from hospitalized populations and interactions among these conditions remain unclear.

Purpose: To evaluate the risk of MACE in the population with risk of OSAHS using the STOP-BANG questionnaire.

Methods: We performed a prospective study in an academic hospital from 2017 to 2018. Data included demography, admissions, STOP-BANG score and CR using AHA scores. The primary outcome was risk of MACE in participants with low risk of OSAHS (STOP-BANG 0-2 points), risk of OSAHS (≥3 points) and risk of moderate/severe OSAHS (≥5 points). Risk of MACE was evaluated using odds ratios (OR), and average CR was evaluated using the t-test.

Results: A total of 441 participants were included. The cumulative prevalence of STOP BANG ≥3 points was 80.9%, and that of ≥5 points was 41.6%. OR of MACE ≥3 points was 3.93 (CI 2.08-7.24) (p < 0.001) compared with <3 points, and Average CR was 10.91% (SD ± 2.13) at <3 points versus 24.3% (SD ± 1.24) for ≥3 points for ≥5 points OR of MACE was 1.72 (CI 1.18-2.59) (p = 0.005) and average CR was 26.14% (SD ± 1.63). However, after multivariable analysis, gender differences and previous heart failure were independently associated to MACE.

Conclusion: The risk of OSAHS in the hospitalized population is high. This population has a higher risk of MACE and higher CRs than do low-risk participants. Conversely, gender and heart failure are potential cofounders.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2019.02.019DOI Listing

Publication Analysis

Top Keywords

risk mace
12
risk osahs
12
points risk
12
≥3 points
12
risk
10
prevalence bang
8
cardiovascular events
8
cardiovascular risk
8
osahs stop-bang
8
≥5 points
8

Similar Publications

While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effectively manage chronic hepatitis B, their long-term effects on lipid metabolism and cardiovascular outcomes remain unclear. This study compares the impact of ETV, TDF, and treatment-naïve (control group) on hyperlipidemia and major adverse cardiac events (MACE) in people living with chronic hepatitis B (PLWHB). We used claim data from the South Korean National Health Insurance Service.

View Article and Find Full Text PDF

Background: Evolving evidence suggests that patients undergoing treatment with Janus kinase inhibitors (JAKi) may face an increased risk of cardiovascular events, malignancies, and serious infections.

Objectives: We assessed cardiovascular, malignancy, and serious infection risks associated with JAKi use compared to tumor necrosis factor inhibitor (TNFi) use, which served as the active comparator, in patients with rheumatoid arthritis (RA) or ulcerative colitis (UC).

Methods: This study emulated a target trial using South Korea's nationwide claims database (2013-2023).

View Article and Find Full Text PDF

Background: Thrombolysis in Myocardial Infarction (TIMI) risk score in patients with ST-segment elevation myocardial infarction (STEMI) is associated with major adverse cardiovascular events (MACE). This study aimed to develop a prediction model based on the TIMI risk score for MACE in STEMI patients after percutaneous coronary intervention (PCI).

Methods: We conducted a retrospective data analysis on 290 acute STEMI patients admitted to the Affiliated Hospital of Yangzhou University from January 2022 to June 2023 and met the inclusion criteria.

View Article and Find Full Text PDF

Background: Ceramide, a key molecule in sphingolipid metabolism, is recognized as a standalone predictor of long-term major adverse cardiac events (MACE). We explore if integrating the global registry of acute coronary events (GRACE) score with the ceramide risk score (ceramide test 1, CERT1) improves MACE prediction in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).

Methods: This cohort study included 210 participants with ACS undergoing PCI.

View Article and Find Full Text PDF

Effect of hyperhomocysteinemia on the prognostic value of triglyceride glucose index in patients with acute coronary syndrome.

Front Cardiovasc Med

January 2025

Beijing Key Laboratory of Precision Medicine of Coronary Atherosclerotic Disease, Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart Lung and Blood Vessel Disease, Clinical Center for Coronary Heart Disease, Capital Medical University, Beijing, China.

Background: The prognostic value of triglyceride-glucose (TyG) has been well described in patients with coronary artery disease (CAD). Hyperhomocysteinemia (HHcy) promotes insulin resistance and has also been regarded as a potential risk factor for cardiovascular disease. However, the prognostic value of TyG in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and the interaction between TyG and HHcy remain unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!